为什么以及由胰岛素衍生性氨基粉症减少胰岛素吸收多少? 一个范围广泛的审查
Ai Ibuki1, Mayu Fukuda2, Tomoko Akase2
1Department of Adult Health Nursing, Faculty of Nursing, Kyoritsu Women's University.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
|October 1, 2023
概括
胰岛素衍生局部粉症 (IDLA) 显著降低胰岛素吸收,使糖尿病患者的血糖控制恶化. 关键机制包括血流受损和胰岛素在注射部位与粉样蛋白纤维结合.
科学领域:
- 内分泌学 在内分泌学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰岛素治疗对于治疗糖尿病至关重要.
- 胰岛素衍生局部粉症 (IDLA) 是重复注射胰岛素导致的皮肤并发症.
- 在糖尿病患者中,IDLA可能导致血糖控制不佳.
研究的目的:
- 审查和更新关于IDLA降低胰岛素吸收程度的知识.
- 探索IDLA位点胰岛素吸收受损背后的机制.
主要方法:
- 进行了关于胰岛素吸收减少及其机制的文献搜索.
- 选择了九个相关的参考文献 (七个关于吸收,四个关于机制).
主要成果:
- 在IDLA部位的胰岛素吸收比正常部位低27-94%.
- 与非触觉部位相比,在可触摸的IDLA部位观察到胰岛素吸收显著降低.
- 确定了四种机制:皮下血流减少,胰岛素吸附到粉样纤维,皮下扩散受损,以及物理因素 (例如,胰岛素制剂震动).
结论:
- IDLA 显著损害了胰岛素的吸收,有助于低于最佳的血糖控制.
- 多种机制有助于IDLA中的胰岛素吸收不良.
- 建议对这些机制进行进一步的体内研究.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin: Dosing Regimen and Adverse Effects
198
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
198
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Insulin: Biosynthesis, Chemistry, and Preparation
415
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
415
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196


